AI-powered search
AI-powered search

Live Evaluations

Take the Challenge to Manage Moderate-to-Severe Psoriasis From Head-to-Toe: FCPANP23 CME Satellite Symposium

About

CME Satellite Symposium: Take the Challenge to Manage Moderate-to-Severe Psoriasis From Head-to-Toe

This activity is supported by an educational grant from Lilly.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify the relationship between psoriasis, psoriatic arthritis and biologics

  • Describe the role of IL-17 inhibitors for the management of moderate-to-severe plaque psoriasis in challenging body areas such as, nails, scalp, genitals, palms, and soles of the feet

  • Recognize patients who would benefit from IL-17 inhibitors for the management of moderate-to-severe plaque psoriasis in challenging body areas

  • Discuss how PAs and NPs can work in a multidisciplinary team to manage patients with moderate-to-severe plaque psoriasis in challenging body areas

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Brad
Brad Glick, DO, MPH

Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Hialeah, FL

Benjamin
Benjamin Lockshin, MD

EVP of Strategic Initiatives
Director of the Clinical Trials Center
Assistant Professor
US Dermatology Partners
Georgetown University
Rockville, MD

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

Brad P. Glick, DO, MPH

Ownership interest: Top MD stock

Benjamin Lockshin, MD

Grant/Research Support: Abbvie, Eli Lilly, Celgene, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Pfizer, Leo, Arcutis, Dermavant 

Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Dermavant, Arcutis, Leo 

Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly, Regeneron, Sanofi Genzyme, Dermavant, Arcutis, Leo

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved